



Biological characterization of an injectable platelet-rich fibrin mixture consisting of autologous albumin gel and liquid platelet-rich fibrin (Alb-PRF)

Masako Fujioka-Kobayashi, Benoit Schaller, Carlos Fernando De Almeida Barros Mourão, Yufeng Zhang, Anton Sculean & Richard J. Miron

To cite this article: Masako Fujioka-Kobayashi, Benoit Schaller, Carlos Fernando De Almeida Barros Mourão, Yufeng Zhang, Anton Sculean & Richard J. Miron (2021) Biological characterization of an injectable platelet-rich fibrin mixture consisting of autologous albumin gel and liquid platelet-rich fibrin (Alb-PRF), *Platelets*, 32:1, 74-81, DOI: [10.1080/09537104.2020.1717455](https://doi.org/10.1080/09537104.2020.1717455)

To link to this article: <https://doi.org/10.1080/09537104.2020.1717455>



Published online: 20 Jan 2020.



Submit your article to this journal [↗](#)



Article views: 248



View related articles [↗](#)



View Crossmark data [↗](#)



Citing articles: 7 View citing articles [↗](#)

ORIGINAL ARTICLE



Biological characterization of an injectable platelet-rich fibrin mixture consisting of autologous albumin gel and liquid platelet-rich fibrin (Alb-PRF)

Masako Fujioka-Kobayashi¹, Benoit Schaller¹, Carlos Fernando De Almeida Barros Mourão², Yufeng Zhang³, Anton Sculean⁴, & Richard J. Miron⁴

¹Department of Cranio-Maxillofacial Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ²Department of Oral Surgery, Dentistry School, Fluminense Federal University, Niterói, Rio De Janeiro, Brazil, ³Department of Oral Implantology, University of Wuhan, Wuhan, China, and ⁴Department of Periodontology, University of Bern, Bern, Switzerland

Abstract

Platelet-rich fibrin (PRF) has been proposed as an autologous membrane with the advantages of host accumulation of platelets and leukocytes with entrapment of growth factors. However, limitations include its faster resorption properties (~2 weeks). Interestingly, recent studies have demonstrated that by heating a liquid platelet-poor plasma (PPP) layer, the resorption properties of heated albumin (albumin gel) can be extended from 2 weeks to greater than 4 months (e-PRF). The aim of the present study was to characterize the biological properties of this novel regenerative modality. Whole blood collected from peripheral blood in 9-mL plastic tubes was centrifuged at 700 g for 8 minutes. Thereafter, the platelet-poor plasma layer was heated at 75°C for 10 minutes to create denatured albumin (albumin gel). The remaining cells and growth factor found within the buffy coat layer (liquid PRF) were thereafter mixed back together with the cooled albumin gel to form Alb-PRF. Histological analysis, including the distribution of cells within Alb-PRF, was then performed. Seven different growth factor release kinetics from Alb-PRF were characterized up to 10 days, including PDGF-AA, PDGF-AB, PDGF-BB, TGF-β1, VEGF, IGF and EGF. Thereafter, gingival fibroblast cell responses to Alb-PRF were investigated by means of a live/dead assay at 24 hours; migration assay at 24 hours; proliferation assay at 1, 3 and 5 days; real-time PCR for the expression of TGF-β and collagen 1a2 at 3 and 7 days; and collagen 1 immunostaining at 14 days. It was first observed histologically that viable cells were evenly distributed throughout the Alb-PRF formulation. Growth factor release demonstrated a slow and gradual release, particularly for TGF-β1 and PDGF-AA/AB, during the entire 10-day period. Alb-PRF also exhibited statistically significantly higher cell biocompatibility at 24 hours and statistically significantly induced greater fibroblast proliferation at 5 days when compared to those of control TCP. Alb-PRF further induced statistically significantly greater mRNA levels of TGF-β at 3 and 7 days, as well as collagen 1 at 7 days. The present results indicate that Alb-PRF possesses regenerative properties induced by the slow and gradual release of growth factors found in liquid PRF via albumin gel degradation. Future studies are thus warranted to fully characterize the degradation properties of Alb-PRF *in vivo* and explore future clinical applications in various fields of medicine.

Keywords

Albumin, fibrin, fibroblasts, platelet-rich fibrin, regeneration, wound healing

History

HistoryReceived 17 October 2019
Revised 3 January 2020
Accepted 6 January 2020
Published online 23 January 2020

Introduction

A number of different surgical techniques, biomaterials and growth factors have been utilized in regenerative medicine and dentistry to speed the formation of either hard or soft tissues [1–4]. While much advancement has been made with respect to the use of biological agents as key mediators of tissue regeneration, some disadvantages have also been reported, including their associated high costs and potential risk of inflammation [5–7]. Nevertheless, biological agents such as recombinant human platelet-derived growth factor (rhPDGF) and bone morphogenetic protein-2 (rhBMP2) play pivotal roles in modern medicine for the regeneration of complex defects.

The use of autologous platelet concentrates has also gained tremendous momentum in recent years as a low-cost regenerative modality with the ability to stimulate tissue neoangiogenesis [4,8,9]. Platelet-rich plasma (PRP) was a first-generation platelet concentrate that favored up to a 6–8-fold increase in platelet concentrations [10–12]. Early experiments revealed the ability of several key growth factors found in blood, including PDGF, transforming growth factor beta 1 (TGF-β1), and vascular endothelial growth factor (VEGF), to be found at higher concentrations when compared to those of whole blood, thus favoring modulation of tissue repair and wound healing [13–18].

More recently, platelet-rich fibrin (PRF) was proposed as a platelet concentrate derived from whole blood without the use of anticoagulants [19,20]. PRF involves the formation of a fibrin clot following centrifugation and may be utilized as a regenerative agent

with specific concentrations of host platelets and leukocytes as well as autologous growth factors. Furthermore, modifications to protocols as well as centrifugation tubes have further allowed for a working liquid-PRF that may be utilized as an injectable modality similar to PRP[21].

One of the main limitations of PRF has been its short *in vivo* turnover rate. In regenerative dentistry, it provides only a limited ability to act as a true 'barrier membrane' since its use is associated with a typical 10–14-day resorption period *in vivo*[22]. An interesting attempt using the heat-compression technique with PRF membranes was introduced by Kawase et al., which aimed to use PRF membranes for guide tissue regeneration (GTR) treatment. The heat compressed PRF was observed for at least 3 weeks postimplantation *in vivo*, whereas the control PRF membranes were completely resorbed within 2 weeks[22]. Furthermore, in facial esthetics and plastic surgery, to overcome the rapid degradation of plasma and keep volume stabilization, a novel technique was developed whereby platelet-poor plasma (PPP) containing mainly roughly 60% albumin is heated at 75 Celsius for 10 minutes to allow for the denaturation and breaking of many of the weak linkages or bonds (*e.g.*, hydrogen bonds) within its protein molecule[23]. Following this process, the proteins are then restructured in a more densely organized protein structure with extended resorption properties for up to 4–6 months [23–25]. However, despite the longer-lasting heat-treated PRF/PPP, a lower regenerative potential is easily expected, since no cells/growth factors in the heat-treated PRF/PPP are capable of enduring the denaturation process (thermal heating). For these reasons, a process whereby reintroduction of the platelet-rich layer from the buffy coat is mixed back into heated PPP (albumin gel) once cooling occurred (termed Alb-PRF)[23].

In view of previous research to date on the topic[23], currently, no single study has investigated or characterized the biological properties of Alb-PRF, which may represent a potential improvement in PRF-based clinical applications. Therefore, the aim of the present study was to perform histological evaluation including the distribution of cells within Alb-PRF and to characterize the release of seven key growth factors found in blood up to a 10-day period, including PDGF-AA, PDGF-AB, PDGF-BB, TGF- β 1, VEGF, epidermal growth factor (EGF) and insulin growth factor 1 (IGF-1). Then, cell biocompatibility, migration potential, proliferation assay and expression of TGF- β 1 and collagen 1 were investigated in human gingival fibroblasts.

Materials and Methods

Preparation of an Albumin Gel-platelet-rich Fibrin Mixture (Alb-PRF) (Figure 1)

Blood samples were collected with the informed consent of 6 volunteer donors. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. No ethical approval was required for this study because human samples were not identified, as previously described[21]. Nine milliliters of blood in plastic tubes was centrifuged at 700 *g* for 8 minutes using an Eppendorf centrifugate 5702 machine (Hamburg, Germany). The upper layer (platelet-poor plasma layer) was collected in 2-mL syringes and heated at 75°C for 10 minutes to create denatured albumin (albumin gel). Following heating, the albumin gel was allowed to cool to room temperature for 10 minutes. Then, liquid PRF including remaining cells and growth factor found within the buffy coat layer was thereafter mixed back together with the cooled albumin gel to form Alb-PRF using a female-female luer lock connector. This combination allowed that both the lower-resorption properties of the albumin gel along with the higher cell content and growth factor

content of the liquid PRF layer to be remixed. The injectable Alb-PRF gels were then transferred into 6-well cell culture plates forming a gelated membrane.

Histological sample preparation

The Alb-PRF specimens were trimmed to an 8-mm diameter with a biopsy punch (STIEFEL, Middlesex, UK) and fixed in 4% formaldehyde in phosphate-buffered saline (PBS) on ice and embedded in Polyfreeze tissue freezing medium (Sigma, St. Louis, MO, USA) after sucrose equilibration. The frozen specimens were sectioned into 5- μ m-thick slices in the chamber of a cryomicrotome (Hyrax C60, Zeiss, Oberkochen, Germany) with an adhesive film (Cryofilm Type 2C(16UF), Section-Lab, Hiroshima, Japan) using Kawamoto's film method[26]. The sections were stained with hematoxylin and eosin (H&E; Section-Lab). The images were captured with a digital microscope (VHX-6000, Keyence, Osaka, Japan).

Protein Quantification with ELISA

In order to determine the amount of released growth factors from Alb-PRF, samples in 5 mL of culture media (DMEM, Gibco, Life Technologies, Carlsbad, CA, USA) were placed into a cell incubator at 37°C to allow for growth factor release into the culture media. At 15 minutes, 60 minutes, 8 hours, 1 day, 3 days and 10 days, 5 ml of culture media was collected, frozen and replaced with 5 ml of additional culture media. Protein quantification was carried out using ELISA. At the desired time points, PDGF-AA (DY221, range = 15.60–1,000 pg/ml), PDGF-AB (DY222, range = 15.60–1,000 pg/ml), PDGF-BB (DY220, 31.20–2,000 pg/ml), TGF- β 1 (DY240, range = 31.20–2,000 pg/ml), VEGF (DY293B, range = 31.20–2,000 pg/ml), EGF (DY236, range = 3.91–250 pg/ml) and IGF-1 (DY291, range = 31.20–2,000 pg/ml) (DuoSet, R&D Systems, Minneapolis, MN, USA) were assessed according to the manufacturer's protocol as previously described[27]. Absorbance was measured at 450 nm and 540 nm using a microplate reader (TECAN Infinite200 pro, Tecan Group Ltd., Männedorf, Switzerland), and the difference values were used for further calculation. Each condition was measured from 6 participants in duplicate.

Cell Culture

Alb-PRF were incubated in cell culture medium for 3 days at 37°C; thereafter, the conditioned medium was collected and utilized in future experiments. Human gingival fibroblasts (HGF-1) were purchased from ATCC (Manassas, VA, USA). All cells were detached from tissue culture plastic using 0.25% EDTA-Trypsin (Gibco) prior to reaching confluency. Cells were cultured in a humidified atmosphere at 37°C in growth medium consisting of DMEM (Gibco), 10% fetal bovine serum (FBS; Gibco), and 1% antibiotics (Gibco). Cells were seeded with 20% conditioned medium from Alb-PRF contained within growth medium at a density of 10,000 cells for cell viability and proliferation experiments and 50,000 cells for real-time PCR per well in 24-well plates. DMEM incubated and collected at the same time as the Alb-PRF conditioned medium was used as a control sample.

Cell Viability

At 24 hours post cell seeding on ϕ 13-mm plastic tissue culture coverslips (Sarstedt, Newton, NC, USA), cells were evaluated using a live-dead staining assay according to the manufacturer's protocol (Enzo Life Sciences AG; Lausen, Switzerland). Fluorescent images were quantified with a fluorescent microscope (Nikon Eclipse E800, Nikon, Tokyo, Japan). Thereafter, cells were expressed as percentages of live versus dead cells following cell culture growth with Alb-PRF.




Figure 1. Alb-PRF preparation protocol. 1) Whole blood (9 mL) was centrifuged at 700 g for 8 minutes. The upper layer (yellow layer) shows the liquid plasma layer. 2) The most upper layer of platelet-poor plasma (PPP) was collected in a syringe. 3) The collected PPP was heated in a heat block device at 75°C for 10 minutes and thereafter 4) cooled to room temperature for approximately 10 minutes. An injectable albumin gel was then prepared. 5) The liquid platelet-rich layer (liquid-PRF), including the buffy coat layer with accumulated platelets and leukocytes, was collected in a separate syringe. 6) The albumin gel and native liquid PRF were then thoroughly mixed by utilizing a female-female luer lock connector. 7) Injectable Alb-PRF in final ready form.

Cell Migration Assay

The migration assay was performed using a 24-well plate and polyethylene terephthalate filters with a pore size of 8 μm (ThinCert™, Greiner Bio-One GmbH, Frickenhausen, Germany). After starving the cells in DMEM containing 0.5% FBS for 12 hours, 10,000 resuspended cells were seeded in the upper compartment in

DMEM containing 0.5% FBS. The 20% conditioned medium in DMEM containing 10% FBS was filled into the lower compartment of the wells. After 24 hours, cells were fixed with 4% formaldehyde for 2 minutes. Thereafter, cells were permeabilized by methanol (Sigma) for 15 minutes and stained with Giemsa solution (MERCK, Darmstadt, Germany) for 20 minutes. The upper side of

the filter membrane was rinsed and gently wiped by a cotton swab to remove the cell debris. The numbers of cells on the lower side of the filter were counted by the counting tool of the digital microscope (Keyence).

Proliferation Assay

HGF-1 cells were quantified by a luminescent cell viability assay (CellTiter-Glo®, Promega, Madison, WI, USA) at 1, 3 and 5 days. At desired time points, living cells were quantified using a luminescence plate reader (TECAN Infinite200 pro).

Real-time PCR Analysis

Total RNA was harvested at 3 and 7 days post-stimulation of HGF-1 cells to investigate the mRNA levels of TGF- β and collagen 1a2 (COL1a2). Primer and probe sequences for genes were fabricated with primer sequences according to Table 1. RNA isolation was performed using a High Pure RNA Isolation Kit (Roche, Basel, Switzerland). A Nanodrop 2000 (Thermo, Wilmington, DE, USA) was used to quantify total RNA levels. Real-time RT-PCR was performed using the GoScript™ Reverse Transcription system (Promega) and quantified on an Applied Biosystems 7500 fast machine using GoTaq® qPCR Master Mix (Promega). The $\Delta\Delta C_t$ method was used to calculate gene expression levels normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Collagen Immunofluorescent Staining

At 14 days post seeding on plastic tissue culture coverslips, HGF-1 cells were fixed with 4% formaldehyde for 10 minutes, followed by PBS containing 0.2% Triton X-100 and blocked in PBS containing 1% bovine serum albumin (BSA, Sigma) for 1 hour to permeabilize the cells. Subsequently, the cells were incubated overnight at 4°C with mouse monoclonal collagen type I (COL-1) antibodies (sc-59772, Santa Cruz, Dallas, TX, USA) diluted 1:200 in PBS containing 1% BSA. After washing with PBS, cells were incubated for 1 hour at 37°C with FITC-conjugated mouse IgG binding proteins (sc-516140, Santa Cruz) diluted 1:100 in PBS containing 1% BSA. Prior to viewing, samples were mounted with Vectashield containing DAPI nuclear staining (Vector, Burlingame, CA, USA). Images were captured by a Nikon Eclipse E800 fluorescence microscope. The optical density of the fluorescent collagen staining was quantified from 3 independent experiments using ImageJ software (NIH, Bethesda, MD, USA).

Statistical Analysis

Means and standard errors were calculated, and the data were analyzed for statistical significance using an unpaired t-test for the cell viability, migration assay, and collagen staining and two-way analysis of variance for the proliferation assay and real-time PCR analysis with the Bonferroni test (p values < .05 was considered

significant) by GraphPad Prism 8.2 software (GraphPad Software, Inc., La Jolla, CA, USA).

Results

Microscopic Observation of Alb-PRF

The frozen sections of Alb-PRF were prepared using film transfer methods to avoid the shrinkage of samples. H&E staining of Alb-PRF sections showed two composite structures with denatured liquid PRF (albumin gel) particles and gelated liquid PRF (Figure 2a–c). The loose matrix structure presented gelated liquid PRF, including several leucocytes entrapped within the fibrin fibers (Figure 2d). The eosin-stained dense structures showed albumin gel, namely, denatured plasma components including few leukocytes (Figure 2e).

Growth Factor Release from Alb-PRF

The release of growth factors from Alb-PRF was investigated by ELISA, including PDGF-AA, PDGF-AB, PDGF-BB, TGF- β 1, VEGF, EGF and IGF-1 (Figure 3). Alb-PRF demonstrated a continuing release of growth factors up to 10 days (Figure 3a). The total release of growth factor calculations revealed that TGF- β 1 released the highest quantities of growth factors among the 7 tested, followed by PDGF-AA and PDGF-AB (Figure 3b).

Biocompatibility of Alb-PRF on Human Gingival Fibroblasts

In the first cell culture experiment, the effects of Alb-PRF were investigated on the cell viability of human gingival fibroblasts (HGF-1 cells). It was found that Alb-PRF demonstrated excellent cell biocompatibility by demonstrating most notably high living cells (green cells, Figure 4a) with very few observable apoptotic cells (red cells). The quantified data suggested that Alb-PRF was fully biocompatible under the present *in vitro* cell culture model (Figure 4b).

Influence of Alb-PRF on Human Gingival Fibroblast Activity

Alb-PRF was then investigated on gingival fibroblasts for the potential of cell migration, proliferation and expression of TGF- β and COL1 (Figure 4c–g). Alb-PRF induced comparable cell migration when compared to that of control media (Figure 4c). Thereafter, a proliferation assay demonstrated that Alb-PRF induced significantly higher cell numbers at 5 days when compared to those of the control (Figure 4d). Investigation into mRNA levels revealed that Alb-PRF was able to significantly increase TGF- β expression at 3 and 7 days postseeding when compared to expression in the control (Figure 4e). Similarly, Alb-PRF significantly increased the mRNA levels of COL1a2 on 7 day (Figure 4f). However, a nonsignificant increase in COL1 immunostaining was observed in the Alb-PRF group on 14 day (Figure 4g).

Discussion

The present *in vitro* study has investigated the regenerative potential of Alb-PRF through histological evaluation, growth factor release, and cell activity. To date, no experimental data exist regarding the combination of liquid PRF mixed with albumin gel. Currently, all known devices have utilized either albumin gel alone, which is completely devoid of cells and growth factors owing to the high processing temperatures, or have investigated liquid PRF, which has more cellular activity but lacks degradation properties past 14 days. By combining both technologies, our group hypothesized that Alb-PRF would demonstrate viable cells capable of releasing growth factors over time while simultaneously improving the cellular activity of gingival fibroblasts.

Table 1. Primers for quantitative RT-PCR (F = forward primer; R = reverse primer).

Gene	Primer Sequence (5' – 3')
hTGF- β 1 F	ACTACTACGCCAAGGAGGTCA
hTGF- β 1 R	TGCTTGAACCTTGTCATAGATTTTCG
hCOL1a2 F	CCCAGCCAAGAAGCTGGTATAGG
hCOL1a2 R	GGCTGCCAGCATTGATAGTTTC
hGAPDH F	AGCCACATCGCTCAGACA
hGAPDH R	GCCCAATACGACCAATCC





Figure 2. Microscopic observation of the Alb-PRF membrane. (a) A trimmed 8-mm Alb-PRF membrane sized with a biopsy punch. (b) H&E staining of the Alb-PRF section. (c) A high magnified view of the image shown in (b). Two components, eosin-stained filler particle-like structure and matrix, are observed. (d) The high magnified view of the native liquid PRF portion shown in (c). Leukocytes were observed in the fibrin matrix. (e) The high magnified view of denatured liquid PPP (albumin gel) shown in (c). A dense fiber network was observed with few leukocytes.

Figure 3. (a) ELISA protein quantification at each time point of PDGF-AA, PDGF-AB, PDGF-BB, TGF-β1, VEGF, EGF and IGF-1 over a 10-day period. (b) Total accumulated growth factor released over a 10-day period for PDGF-AA, PDGF-AB, PDGF-BB, TGF-β1, VEGF, EGF and IGF-1. The ELISA experiment was performed in duplicate from six independent participants for each growth factor and the means and standard errors were presented.



Interestingly, to the best of the authors' knowledge, this is the first study that has investigated Alb-PRF at the cellular level. By heating and denaturing albumin, a modification in the secondary structure after heating transforms the matter into a tridimensional structure.

During this heating process, new hydrogen and disulfide ligations in the enzymes are created, which favors a larger tridimensional structure with drastic changes in its resorption properties and improves its stability over time[28]. Results from preclinical animal studies have




Figure 4. Cell behavior when stimulated with Alb-PRF. (a, b) Live/Dead assay at 24 hours of human gingival fibroblasts treated with Alb-PRF. (a) The merged fluorescent images of live/dead staining with viable cells appearing in green and dead cells in red. (b) Cell viability was quantified as the percentage of living cells. Live/dead assay was performed in triplicate from three independent experiments and cell numbers were counted in the acquired images. (* denotes significantly higher than the control group, $p = .0034$.) (c, d) Effects of Alb-PRF on human gingival fibroblast (c) cell migration at 24 hours and (d) cell proliferation at 1, 3 and 5 days. The migration assay and proliferation assay were performed in triplicate from three independent experiments. (* denotes significantly higher than the control group at each time point for the proliferation experiment, $p = .0185$ at 1 day, $p = .0181$ at 5 days.) (e, f) Real-time PCR of human gingival fibroblasts cultured with Alb-PRF at 3 and 7 days for mRNA levels of (e) TGF- β and (f) COL1a2. The real-time PCR was performed in triplicate from three independent experiments. (* denotes significantly higher than the control group; for TGF- β mRNA expressions, $p < .0001$ at 3 days and $p = .0112$ at 7 days; for COL1a2, $p = .0005$ at 7 days.) (g, h) Immunofluorescent collagen 1 (COL1) staining of human gingival fibroblasts treated with Alb-PRF at 14 days. (g) The merged fluorescent images of COL1 staining (green) with DAPI staining (blue). (h) Quantified values of COL staining in comparison with control samples. COL staining assay was quantified in the acquired images in triplicate from three independent experiments.

shown that while standard PRF resorbs within a 2-week timeframe, denatured albumin lasts up to 4–6 months when implanted into a subcutaneous nude animal model (currently under review). This change in processing adds approximately 20 minutes to the current protocol time to fabricate Alb-PRF, as highlighted in Figure 1; however, the clinical benefits could favor this technology for many clinical indications in medicine and dentistry. It therefore becomes possible to create a true ‘barrier’ or ‘filler’ biomaterial derived from 100% autologous whole blood with drastically extended resorption properties. Furthermore, the ability to harvest large doses from a simple blood draw makes this biomaterial an extremely attractive regenerative agent that may be harvested at low cost from a peripheral vein.

In the present study, it was first observed that by utilizing a standard female-female luer lock connector between two syringes, it was possible to actively infiltrate albumin gel with cells

and growth factors from liquid PRF. Figure 2 further demonstrates that the Alb-PRF matrix appeared as a dense scaffold with cells present spanning throughout the autologous biomaterial. This differs drastically from previously utilized albumin gel protocols in that the reintroduction of cells, highly concentrated specifically within the buffy coat layer, is capable of replantation back within the Alb-PRF scaffold. This represents a novel strategy for improving both the clinical performance of either liquid PRF alone or albumin gel alone.

In the present study, it was first observed that when gingival fibroblasts were cultured with Alb-PRF, an actual improvement in growth factor release was experienced from 15 minutes to 10 days (Figure 3). Specifically, TGF- β 1 was surprising and drastically increased in concentration, with a nearly 10-fold increase in growth factor release from baseline at 15 minutes up to 10 days. In contrast, other growth factors such as VEGF observed little

differences/increases in concentration over time. Previous data published by our group have also demonstrated that the previously investigated release of growth factors from PRF membranes and liquid injectable PRF (i-PRF) demonstrated a similar trend, whereby TGF- β 1 and PDGF growth factors were released in the highest quantities [21,29,30]. This illustrates that the cells present in Alb-PRF are fully vital and release growth factors in a similar manner to previously published data on standard solid-based and liquid-based PRF matrices.

The main aim of the present study was to investigate the regenerative potential of Alb-PRF at the cellular level. As such, a gingival fibroblast model was utilized owing to our group's previous experience utilizing this cell type as well as owing to the ability of PRF to promote soft tissue healing when compared to healing of hard tissues [4,31]. It was first observed that culturing fibroblasts with Alb-PRF actually significantly improved their cellular viability, as confirmed using a live/dead cell assay (Figure 4a). It also promoted cell proliferation at 5 days and induced a significant increase in TGF β 1 and COL1a2 mRNA expression at either 3 or 7 days postseeding. This highlights that unlike traditional biomaterials that may be utilized in dentistry and medicine with extended resorption properties (such as polymers in the facial esthetic field or nonresorbable PTFE membranes in dentistry), this completely autologous biomaterial is not only low cost but also actually promotes the regeneration of cells within its surrounding implanted microenvironment. It also avoids any potential foreign body reaction since it is totally autologous and additionally improves the growth factor release from local cells. Future animal research will be pivotal to further understand the full potential of Alb-PRF in clinical practice.

Not surprisingly, the scientific literature still lacks adequate reports, either in the form of case series or randomized trials, on the real clinical advantages pertaining to the use of Alb-PRF. Since Alb-PRF offers significant structural advantages in its degradation properties, it remains to be investigated if in fact Alb-PRF would release growth factors for even further time periods past 10–14 days owing to its slower degradation rate.

Several clinical applications may also be conceptualized, providing almost immediate impact. For example, it is known that the use of titanium mesh for ridge augmentations in dentistry is associated with a relatively high rate of mesh exposure, with reports up to 50% [32–35]. Currently, many clinicians have utilized PRF overtop of a titanium mesh or overtop of a Ti-mesh +collagen membrane to minimize the rate of exposure. By utilizing a longer-lasting Alb-PRF membrane for such an application, it would theoretically be hypothesized that further improvements would be expected. Future clinical studies are therefore needed. Similarly, many filler-type biomaterials are utilized in facial esthetics. While many patients prefer the 'natural' and more autologous use of liquid plasma, the main drawback to date has been the faster than desired resorption rate of liquid PRF with relatively quick facial volume loss. Therefore, by utilizing Alb-PRF, a preferential extended clinical outcome may be expected. Future research is also needed in this field.

In conclusion, the present study revealed for the first time the *in vitro* positive regenerative properties of Alb-PRF as a low substitution platelet concentrate with extended resorption properties. Alb-PRF may be used as an injectable form utilizing a female-female luer lock connector or with a scaffold or membrane form by pre-forming in custom-sized trays to create specific and desirable shapes. Furthermore, Alb-PRF remains moldable upon either injection or during its shaping with a long-lasting growth factor release curve capable of stimulating tissue regeneration over extended periods of time. Future animal studies and clinical testing are therefore needed to further validate this novel regenerative technology.

Conflict of Interest

Richard Miron declares that he has intellectual property on the Bio-Heat technology utilized in this manuscript. All other authors declare no conflict of interest.

References

1. Sanz-Sanchez I, Ortiz-Vigon A, Sanz-Martin I, Figuero E, Sanz M. Effectiveness of lateral bone augmentation on the alveolar crest dimension: a systematic review and meta-analysis. *J Dent Res*. 2015;94:128s–142s. doi:10.1177/0022034515594780
2. Miron RJ, Zhang YF. Osteoinduction: a review of old concepts with new standards. *J Dent Res*. 2012;91:736–744. doi:10.1177/0022034511435260
3. Miron RJ, Sculean A, Cochran DL, Froum S, Zucchelli G, Nemcovsky C, Donos N, Lyngstadaas SP, Deschner J, Dard M, et al. Twenty years of enamel matrix derivative: the past, the present and the future. *J Clin Periodontol* 2016;43:668–683. doi:10.1111/jcpe.12546
4. Miron RJ, Zucchelli G, Pikos MA, Salama M, Lee S, Guillemette V, Fujioka-Kobayashi M, Bishara M, Zhang Y, Wang HL, et al. Use of platelet-rich fibrin in regenerative dentistry: a systematic review. *Clin Oral Investig* 2017;21:1913–1927. doi:10.1007/s00784-017-2133-z
5. Anusaksathien O, Giannobile WV. Growth factor delivery to re-engineer periodontal tissues. *Curr Pharm Biotechnol*. 2002;3:129–139. doi:10.2174/1389201023378391
6. Carreira AC, Lojudice FH, Halcsik E, Navarro RD, Sogayar MC, Granjeiro JM. Bone morphogenetic proteins: facts, challenges, and future perspectives. *J Dent Res*. 2014;93:335–345. doi:10.1177/0022034513518561
7. Rocque BG, Kelly MP, Miller JH, Li Y, Anderson PA. Bone morphogenetic protein-associated complications in pediatric spinal fusion in the early postoperative period: an analysis of 4658 patients and review of the literature. *J Neurosurg Pediatr*. 2014;14:635–643. doi:10.3171/2014.8.peds13665
8. Castro AB, Meschi N, Temmerman A, Pinto N, Lambrechts P, Teughels W, Quirynen M. Regenerative potential of leucocyte- and platelet-rich fibrin. Part A: intra-bony defects, furcation defects and periodontal plastic surgery. A systematic review and meta-analysis. *J Clin Periodontol*. 2017;44:67–82. doi:10.1111/jcpe.12643
9. Castro AB, Meschi N, Temmerman A, Pinto N, Lambrechts P, Teughels W, Quirynen M. Regenerative potential of leucocyte- and platelet-rich fibrin. Part B: sinus floor elevation, alveolar ridge preservation and implant therapy. A systematic review. *J Clin Periodontol*. 2017;44:225–234. doi:10.1111/jcpe.12658
10. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? *Implant Dent*. 2001;10:225–228. doi:10.1097/00008505-200110000-00002
11. Marx RE. Platelet-rich plasma: evidence to support its use. *J Oral Maxillofac Surg*. 2004;62:489–496. doi:10.1016/j.joms.2003.12.003
12. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1998;85:638–646. doi:10.1016/s1079-2104(98)90029-4
13. Medina-Porqueres I, Alvarez-Juarez P. The efficacy of platelet-rich plasma injection in the management of hip osteoarthritis: a systematic review protocol. *Musculoskeletal Care*. 2015. doi:10.1002/msc.1115
14. Salamanna F, Veronesi F, Maglio M, Della Bella E. New and emerging strategies in platelet-rich plasma application in musculoskeletal regenerative procedures: general overview on still open questions and outlook. *Biomed Res Int*. 2015;2015:846045. doi:10.1155/2015/846045
15. Albanese A, Licata ME, Polizzi B, Campisi G. Platelet-rich plasma (PRP) in dental and oral surgery: from the wound healing to bone regeneration. *Immun Ageing*. 2013;10:23. doi:10.1186/1742-4933-10-23
16. Dohan Ehrenfest DM, Andia I, Zumstein MA, Zhang CQ, Pinto NR, Bielecki T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. *Muscles Ligaments Tendons J* 2014;4:3–9. doi:10.32098/mltj.01.2014.02

17. Maney P, Amornporncharoen M, Palaiologou A. Applications of plasma rich in growth factors (PRGF) in dental surgery: a review. *J West Soc Periodontol Periodontol Abstr.* 2013;61:99–104.
18. Panda S, Doraiswamy J, Malaipattan S, Varghese SS, Del Fabbro M. Additive effect of autologous platelet concentrates in treatment of intrabony defects: a systematic review and meta-analysis. *J Invest Clin Dent.* 2014. doi:10.1111/jicd.12117
19. Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, Dohan AJ, Mouhyi J, Dohan DM. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part V: histologic evaluations of PRF effects on bone allograft maturation in sinus lift. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2006;101:299–303. doi:10.1016/j.tripleo.2005.07.012
20. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2006;101:e45–50. doi:10.1016/j.tripleo.2005.07.009
21. Miron RJ, Fujioka-Kobayashi M, Hernandez M, Kandam U, Zhang Y, Ghanaati S, Choukroun J. Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry? *Clin Oral Investig.* 2017. doi:10.1007/s00784-017-2063-9
22. Kawase T, Kamiya M, Kobayashi M, Tanaka T, Okuda K, Wolff LF, Yoshie H. The heat-compression technique for the conversion of platelet-rich fibrin preparation to a barrier membrane with a reduced rate of biodegradation. *J Biomed Mater Res B Appl Biomater.* 2015;103:825–831. doi:10.1002/jbm.b.33262
23. Mourão C, Gheno E, Lourenço ES, de Lima Barbosa R, Kurtzman GM, Javid K, Mavropoulos E, Benedicenti S, Calasans-Maia MD, de Mello Machado RC. Characterization of a new membrane from concentrated growth factors associated with denatured Albumin (Alb-CGF) for clinical applications: A preliminary study. *Int J Growth Factors Stem Cells Dent* 2018;1:64. doi:10.4103/GFSC.GFSC_21_18
24. Jung SY, Kim HY, Oh HJ, Choi E, Cho MS, Kim HS. Feasibility of autologous plasma gel for tonsil-derived stem cell therapeutics in hypoparathyroidism. *Sci Rep.* 2018;8:11896. doi:10.1038/s41598-018-30454-1
25. Doghaim NN, El-Tatawy RA, Neinaa YME. Assessment of the efficacy and safety of platelet poor plasma gel as autologous dermal filler for facial rejuvenation. *J Cosmet Dermatol.* 2019;18:1271–1279. doi:10.1111/jocd.12876
26. Kawamoto T, Kawamoto K. Preparation of thin frozen sections from nonfixed and undecalcified hard tissues using Kawamoto's film method (2012). *Methods Mol Biol.* 2014;1130:149–164. doi:10.1007/978-1-62703-989-5_11
27. Kobayashi E, Fluckiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, Miron RJ. Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin Oral Investig.* 2016;20:2353–2360. doi:10.1007/s00784-016-1719-1
28. Giancola C, De Sena C, Fessas D, Graziano G, Barone G. DSC studies on bovine serum albumin denaturation. Effects of ionic strength and SDS concentration. *Int J Biol Macromol.* 1997;20:193–204. doi:10.1016/s0141-8130(97)01159-8
29. Fujioka-Kobayashi M, Miron RJ, Hernandez M, Kandam U, Zhang Y, Choukroun J. Optimized platelet-rich fibrin with the low-speed concept: growth factor release, biocompatibility, and cellular response. *J Periodontol.* 2017;88:112–121. doi:10.1902/jop.2016.160443
30. Kobayashi E, Fluckiger L, Fujioka-Kobayashi M, Sawada K, Sculean A, Schaller B, Miron RJ. Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin Oral Investig.* 2016;20:2353–2360. doi:10.1007/s00784-016-1719-1
31. Miron RJ, Fujioka-Kobayashi M, Bishara M, Zhang Y, Hernandez M, Choukroun J. Platelet-rich fibrin and soft tissue wound healing: a systematic review. *Tissue Eng Part B Rev.* 2017;23:83–99. doi:10.1089/ten.TEB.2016.0233
32. Louis PJ, Gutta R, Said-Al-Naief N, Bartolucci AA. Reconstruction of the maxilla and mandible with particulate bone graft and titanium mesh for implant placement. *J Oral Maxillofac Surg.* 2008;66:235–245. doi:10.1016/j.joms.2007.08.022
33. von Arx T, Kurt B. Implant placement and simultaneous ridge augmentation using autogenous bone and a micro titanium mesh: a prospective clinical study with 20 implants. *Clin Oral Implants Res.* 1999;10:24–33. doi:10.1034/j.1600-0501.1999.100104.x
34. Al-Ardah AJ, AlHelal A, Proussaefs P, AlBader B, Al Humaidan AA, Lozada J. Managing titanium mesh exposure with partial removal of the exposed site: a case series study. *J Oral Implantol.* 2017;43:482–490. doi:10.1563/aaid-joi-D-17-00169
35. Maqbool T, Binhammer A, Binhammer P, Antonyshyn OM. Risk factors for titanium mesh implant exposure following cranioplasty. *J Craniofac Surg.* 2018;29:1181–1186. doi:10.1097/scs.0000000000004479